Félix Calderón

Félix Calderón, Scientific Director at GSK Global Health Medicines R&D, started his career in industry in 2007 as a medicinal chemist at GSK. Since then, he has held different leadership roles in anti-infectious and anti-inflammatory areas within the organization being responsible for the identification of multiple lead series, clinical candidates and the validation of a new anti-protozoal target class. He has a broad experience working with external partners and a track record of implementing and delivering new collaborations across diseases. During 2018-2023 he led the Tres Cantos Open Lab, a unique R&D model that brings academic and industrial scientists together to tackle endemic infectious diseases that disproportionally affects LMIC/LIC. Prior to GSK, his background includes a B.Sc. from the Autonoma University of Madrid and training in bioorganic chemistry at the University of Turin (Italy), the Spanish National Council for Scientific Research (CSIC, Ph.D. awarded in 2006), and computational chemistry at the University of California Los Angeles (UCLA).